Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
NCT01108055
Completed
We will combine an oral investigational vascular endothelial growth factor (VEGF inhibitor) called pazopanib which is being studied in kidney cancer will be combined with standard chemotherapy called taxol in patients with relapsed recurrent urothelial cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2017
Locations: Stanford University School of Medicine, Stanford, California +1 locations
Conditions: Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy), Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable
Register for Updates
Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer
NCT01558492
Terminated
The purpose of this study is to look at the clinical benefit of carboplatin and paclitaxel and correlate response to study treatment with biologic parameters (i.e. lab studies of blood, urine, or tissue). It is hoped that this will allow researchers to gain insight into the underlying biology of prostate tumor progression and perhaps predict which patients may benefit from this chemotherapy regimen.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/05/2017
Locations: Weill Cornell Medical College, New York, New York
Conditions: Prostate Cancer
Register for Updates
Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients
NCT02338115
Completed
The purpose of this prospective observational study is to understand the relationship between paclitaxel exposure and development of peripheral neuropathy during treatment.
Gender:
FEMALE
Ages:
19 years and above
Trial Updated:
05/01/2017
Locations: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Conditions: Breast Cancer
Register for Updates
Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer
NCT01227408
Withdrawn
The investigators propose to conduct a clinical trial of neoadjuvant treatment utilizing chemotherapy formulations with favorable toxicity profiles: weekly doxorubicin, PPX and capecitabine. It is expected this combination will at least maintain the efficacy of a traditional chemotherapy regimen but will be associated with less toxicity, particularly nausea, vomiting and alopecia. In order to accomplish this the investigators have designed a chemotherapy regimen whose components (or administrati... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/29/2017
Locations: USC/Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Breast Cancer
Register for Updates
Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer
NCT00459810
Terminated
RATIONALE: Drugs used in chemotherapy, such as paclitaxel poliglumex, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Estradiol may kill prostate cancer cells that no longer respond to hormone therapy. Giving paclitaxel poliglumex together with estradiol may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving paclitaxel poliglumex together with estradiol works in treating patients with stage IV... Read More
Gender:
MALE
Ages:
Between 18 years and 120 years
Trial Updated:
04/26/2017
Locations: UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California +1 locations
Conditions: Prostate Cancer
Register for Updates
Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma
NCT00093119
Completed
This trial will treat patients previously treated for advanced (metastatic) melanoma (skin cancer) with a new chemotherapeutic medicine. The new chemotherapy will be administered weekly in cycles of three weekly doses followed by one week rest. A minimum of three cycles of therapy will be given to determine the anti-tumor response of the new chemotherapy. Patients may continue to stay on therapy a maximum of 9-12 cycles if treatment shows continuing benefit.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2017
Locations: Abraxis BioScience Inc., Durham, North Carolina
Conditions: Melanoma, Metastases
Register for Updates
Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer
NCT01493843
Completed
This multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of carboplatin/paclitaxel and carboplatin/paclitaxel/bevacizumab with and without pictilisib in particpants with previously untreated advanced or recurrent non-small cell lung cancer (NSCLC). Particpants will be randomized to receive 4 cycles of carboplatin (C)/paclitaxel (P) and either pictilisib or placebo, with (participants with non-squamous NSCLC) or without (participants with squamous... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2017
Locations: Alabama Oncology, Birmingham, Alabama +119 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer
NCT01740336
Completed
This multicenter, randomized, single-blind, placebo-controlled, two arm study will evaluate the efficacy and safety of paclitaxel with GDC-0941 versus paclitaxel with placebo in participants with locally recurrent or metastatic breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/21/2017
Locations: Arizona Oncology Associates, PC - NAHOA, Sedona, Arizona +96 locations
Conditions: Breast Cancer
Register for Updates
N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer
NCT01138137
Withdrawn
RATIONAL FOR STUDYING IV NAC AS POTENTIAL CHEMOPROTECTANT: Cisplatin has shown efficacy in the treatment of subjects with epithelial ovarian cancer. Systemic toxicities associated with cisplatin include nephro, oto, and nerve toxicities. It may be possible to reduce the toxicities of cisplatin by administering it in conjunction with IV NAC. NAC may reduce cisplatin related nephro, oto, and nerve toxicities without compromising the effectiveness of the chemotherapy against the ovarian cancer cel... Read More
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
04/19/2017
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Ovarian Carcinoma, Stage 3 or 4, Epithelial Ovarian Carcinoma, Primary Peritoneal Carcinoma
Register for Updates
Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer
NCT01160601
Completed
This is a randomized, open-label, multicenter, phase 2 study comparing Paclitaxel/Carboplatin with or without bavituximab in patients that have previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2017
Locations: Ironwood Cancer and Research Center, Chandler, Arizona +39 locations
Conditions: Non-Squamous Non-Small Cell Lung Cancer
Register for Updates
Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer
NCT00728845
Terminated
RATIONALE: Drugs used in chemotherapy, such as hydroxychloroquine, carboplatin, and paclitaxel and work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cell... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/17/2017
Locations: Cancer Institute of New Jersey at Hamilton, Hamilton, New Jersey +1 locations
Conditions: Lung Cancer
Register for Updates
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
NCT00041119
Completed
This randomized phase III trial studies cyclophosphamide and doxorubicin hydrochloride compared with paclitaxel as adjuvant therapy in treating breast cancer in women with 0-3 positive axillary lymph nodes. Giving additional cancer treatment after surgery may help to lower the risk that the cancer will come back (adjuvant therapy). Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by k... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/12/2017
Locations: Regional Medical Center, Anniston, Alabama +526 locations
Conditions: Breast Cancer
Register for Updates